Wirtschaftlichkeit des Einsatzes von Irbesartan bei Patienten mit Typ-2 Diabetes, Hypertonie und Nephropathie in der Schweiz. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]
Details
Serval ID
serval:BIB_4EC3A2E56B91
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Wirtschaftlichkeit des Einsatzes von Irbesartan bei Patienten mit Typ-2 Diabetes, Hypertonie und Nephropathie in der Schweiz. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]
Journal
Schweizerische Rundschau fur Medizin Praxis
ISSN
1013-2058 (Print)
Publication state
Published
Issued date
03/2006
Volume
95
Number
11
Pages
401-8
Notes
Comparative Study
English Abstract
Journal Article --- Old month value: Mar 15
English Abstract
Journal Article --- Old month value: Mar 15
Abstract
The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy). The objective of this study was to investigate the long-term health economic consequences of this treatment strategy in a Swiss health care setting. This analysis used a Markov model to simulate the progression of nephropathy, life-years and treatment costs over ten years for each of the three treatment options. In additon, sensitivity analyses were performed. Treatment with irbesartan will save CHF 22681/patient as compared with amlodipine and CHF 13847 as compared with standard therapy.
Keywords
Amlodipine/economics/therapeutic use
Angiotensin II Type 1 Receptor Blockers/administration &
dosage/*economics/*therapeutic use
Antihypertensive Agents/administration & dosage/*economics/*therapeutic
use
Biphenyl Compounds/administration & dosage/*economics/*therapeutic use
Calcium Channel Blockers/economics/therapeutic use
Cohort Studies
Cost Savings
Costs and Cost Analysis
Diabetes Mellitus, Type 2/complications/*drug therapy/*economics
Diabetic Nephropathies/*drug therapy/*economics/mortality/surgery
Disease Progression
Follow-Up Studies
Humans
Hypertension/*drug therapy/*economics/etiology
Kidney Failure, Chronic/etiology
Kidney Transplantation/economics
Markov Chains
Multicenter Studies
Placebos
Randomized Controlled Trials
Renal Dialysis
Risk
Sensitivity and Specificity
Switzerland
Tetrazoles/administration & dosage/*economics/*therapeutic use
Time Factors
Pubmed
Create date
25/01/2008 12:55
Last modification date
20/08/2019 14:04